Research & Development News Channel

Targeting a new antibody supersite key to COVID immunity

Scientists are learning that a lesser-studied region on the pandemic coronavirus is recognized by COVID-19 infection-fighting antibodies. These antibodies were identified in blood samples from previously infected patients, and were found to potently prevent the virus from infecting cells.

Leprosy drug holds promise as at-home treatment for COVID-19

A Nature study authored by scientists at Sanford Burnham Prebys Medical Discovery Institute and the University of Hong Kong shows that the leprosy drug clofazimine, which is FDA approved and on the World Health Organization's List of Essential Medicines, exhibits potent antiviral activities against SARS-CoV-2 and prevents the exaggerated inflammatory response associated with severe COVID-19.

Variant B.1.1.7 of COVID-19 associated with a significantly higher mortality rate

The highly infectious variant of COVID-19 discovered in Kent, which swept across the UK last year before spreading worldwide, is between 30 and 100 per cent more deadly than previous strains, new analysis has shown.

A pivotal study, by epidemiologists from the Universities of Exeter and Bristol, has shown that the SARS-CoV-2 variant, B.1.1.7, is associated with a significantly higher mortality rate amongst adults diagnosed in the community compared to previously circulating strains.

New compound targets enzyme linked to autoimmune disorders, severe COVID-19

When the body detects a pathogen, such as bacteria or viruses, it mounts an immune system response to fight this invader. In some people, the immune system overreacts, resulting in an overactive immune response that causes the body to injure itself, which may prove fatal in some cases.

New evidence COVID-19 antibodies, vaccines less effective against variants

New research at Washington University School of Medicine in St. Louis indicates that three new, fast-spreading variants of the virus that cause COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic. With few exceptions, whether such antibodies were produced in response to vaccination or natural infection, or were purified antibodies intended for use as drugs, the researchers found more antibody is needed to neutralize the new variants.

Vaccine development software shows promise in influenza effort, could help defeat coronavirus

A novel computer algorithm that could create a broadly reactive influenza vaccine for swine flu also offers a path toward a pan-influenza vaccine and possibly a pan-coronavirus vaccine as well, according to a new paper published in Nature Communications.

Researchers discover SARS-CoV-2 inhibitors

A research team of pharmacists at the University of Bonn has discovered two families of active substances that can block the replication of the SARS-CoV-2 coronavirus. The drug candidates are able to switch off the the key enzyme of the virus, the so-called main protease. The study is based on laboratory experiments. Extensive clinical trials are still required for their further development as therapeutic drugs.

Research & Development News

Targeting a new antibody supersite key to COVID immunity

Leprosy drug holds promise as at-home treatment for COVID-19

Variant B.1.1.7 of COVID-19 associated with a significantly higher mortality rate

New compound targets enzyme linked to autoimmune disorders, severe COVID-19

New evidence COVID-19 antibodies, vaccines less effective against variants

Vaccine development software shows promise in influenza effort, could help defeat coronavirus

Researchers discover SARS-CoV-2 inhibitors

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs